Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 31,583 shares, a decline of 64.6% from the June 30th total of 89,295 shares. Based on an average daily trading volume, of 42,616 shares, the short-interest ratio is currently 0.7 days. Currently, 0.0% of the shares of the stock are sold short.
Analysts Set New Price Targets
Separately, Weiss Ratings raised Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold”.
Check Out Our Latest Stock Report on Anbio Biotechnology
Anbio Biotechnology Trading Down 0.3%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Featured Stories
- Five stocks we like better than Anbio Biotechnology
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
